Biology and treatment of myelodysplastic syndromes — developments in the past decade
- 1 March 1993
- journal article
- review article
- Published by Springer Nature in Annals of Hematology
- Vol. 66 (3) , 107-115
- https://doi.org/10.1007/bf01697618
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha2bEuropean Journal of Haematology, 2009
- Danazol treatment of myelodysplastic syndromesBritish Journal of Haematology, 2008
- Order of human hematopoietic growth factor and receptor genes on the long arm of chromosome 5, as determined by fluorescence in situ hybridizationAnnals of Hematology, 1993
- The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup studyAnnals of Hematology, 1992
- Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessmentAnnals of Hematology, 1992
- In vivo administration of granulocyte‐macrophage colony stimulating factor enhances neutrophil function in patients with myelodysplastic syndromesBritish Journal of Haematology, 1991
- Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromesAmerican Journal of Hematology, 1991
- The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietinBritish Journal of Haematology, 1991
- Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic SyndromesNew England Journal of Medicine, 1987
- A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndromeNature, 1987